ACE2 News and Research

RSS

A systematic review and meta-analysis of stroke in COVID-19 patients

Fourteen out of every 1,000 COVID-19 patients admitted to hospital experience a stroke, a rate that is even higher in older patients and those with severe infection and pre-existing vascular conditions, according to a report published this week.

28 Oct 2020

Cognitive disorders associated with risk for developing severe COVID-19

Dementia and other cognitive disorders now appear to be risk factors for developing severe COVID-19, according to research from the University of Georgia. The findings highlight the need for special care for populations with these preexisting conditions during the pandemic.

28 Oct 2020

Scientists compare ACE2 interaction with SARS-CoV-2 across species

Like other pathogenic coronaviruses, SARS-CoV-2 crossed the species barrier to cause human disease. This fact motivated the current study, published on the preprint server bioRxiv* in October 2020, which explores the way coronaviruses engage their host cell receptors in a range of animals.

28 Oct 2020

Researchers demonstrate potent antibody that fights against coronavirus

Scientists at Fred Hutchinson Cancer Research Center in Seattle have shown that a potent antibody from a COVID-19 survivor interferes with a key feature on the surface of the coronavirus's distinctive spikes and induces critical pieces of those spikes to break off in the process.

28 Oct 2020

Lianhuaqingwen capsule is effective for treating COVID-19 pneumonia

Lianhuaqingwen (LHQW) capsule, a herb medicine product, has been clinically proved to be effective in coronavirus disease 2019 (COVID-19) pneumonia treatment. However, human exposure to LHQW components and their pharmacological effects remain largely unknown.

28 Oct 2020

Furin cleavage site and D614G on SARS-CoV-2 spike evolved to balance infectivity, stability, cytopathicity

SARS-CoV-2 is the causative agent of COVID-19 disease, currently raging across the world. The virus has now infected more than 43.89 million individuals and claimed over 1.16 million lives. The study titled, "Spike glycoprotein and host cell determinants of SARS-CoV-2 entry and cytopathic effects," is released on the preprint server bioRxiv* in October 2020.

27 Oct 2020

Gut's immune response to SARS-CoV-2 very different from the lung

Megan L. Stanifer et al. study the immune response in the human gut upon SARS-CoV-2 infection. The study published as a bioRxiv* preprint reveals a robust proinflammatory response: a cell type-specific or a tissue-specific regulation of interferon-mediated signaling during SARS-CoV-2 infection.

27 Oct 2020

Scientists identify new therapeutic targets for SARS-CoV-2

To identify new potential therapeutic targets for SARS-CoV-2, a team of scientists at the New York Genome Center, New York University, and the Icahn School of Medicine at Mount Sinai, performed a genome-scale, loss-of-function CRISPR screen to systematically knockout all genes in the human genome.

27 Oct 2020

Lung biomarkers may predict severe COVID-19

Two University of New Mexico researchers postulate certain specific biomarkers' relevance in predicting the potential for progression to severe COVID-19 in a paper published on the preprint server bioRxiv*

27 Oct 2020

Phase 1 trial results of gorilla adenovirus vaccine for COVID-19

A recent study published on the preprint server bioRxiv* in October 2020 reports the development of a novel vaccine based on a simian adenoviral vector obtained from a group C gorilla isolate called GRAd32. This could help speed up vaccine development.

26 Oct 2020

New peptide derivatives that target the SARS-CoV-2 spike protein

In a new study published in the journal Cellular and Molecular Bioengineering, researchers report peptide derivatives, or peptidomimetics, based on the circle residues involved in the interaction of the spike protein and ACE2.

26 Oct 2020

Transcriptomics identifies possible COVID-19 therapies

By using a diverse set of transcriptomic SARS-CoV-2 signatures, US researchers put to use their previously developed drug repositioning pipeline to pinpoint potential drug candidates for the treatment of coronavirus disease (COVID-19). The study is currently available on bioRxiv preprint server.

26 Oct 2020

Study suggests 5’UTR of SARS-CoV-2 might be of pangolin coronavirus origin

Findings from a new genomic sequencing study support the hypothesis that the pangolin was the intermediate host for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that enabled transmission of the virus to humans.

26 Oct 2020

Research uncovers SARS-CoV-2 viral traits critical for the virus in human airways

A new study published on the preprint server bioRxiv* in October 2020 reports the discovery of important viral genomic features that are crucial to its replication in the human airway cells, and its enhancing mutations which increase the rate of replication and determine its target cells.

26 Oct 2020

Small molecules block SARS-CoV-2 spike-ACE2 attachment

The search includes immunological agents, enzyme inhibitors, and soluble competitive inhibitors. Now, a new study published on the preprint server bioRxiv in October 2020 provides preliminary evidence that small molecules can inhibit viral entry by inhibiting spike-ACE2 attachment.

26 Oct 2020

NRP-1 receptor potentiates SARS-CoV-2 infectivity

The COVID-19 pandemic is still actively spreading in many parts of the world, causing redoubled efforts to develop antivirals and vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). A recent study explores the role of a second type of cell surface receptor, called neuropilin, in the virus's entry into the host cell and its subsequent replication.

26 Oct 2020

Neuropilin-1: A new route of SARS-CoV-2 entry

A new study published in the reputed journal Science in October 2020 reports the potential therapeutic value of the second type of host transmembrane receptor, called neuropilins, which attach to the spike protein of SARS-CoV-2 and may enhance its infectivity.

25 Oct 2020